Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tetanus × sargramostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 27 Lymphoma 26 Lymphoma, Follicular 22 Melanoma 21 Leukemia, Lymphocytic, Chronic, B-Cell 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Multiple Myeloma 15 Lymphoma, Non-Hodgkin 15 Lymphoma, Large B-Cell, Diffuse 14 Leukemia, Myeloid, Acute 14 Lymphoma, Large-Cell, Immunoblastic 13 Breast Neoplasms 13 Lymphoma, Mantle-Cell 12 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12 Neoplasms, Plasma Cell 10 Burkitt Lymphoma 10 Prostatic Neoplasms 9 Neuroblastoma 9 Neoplasm Metastasis 9 Myelodysplastic Syndromes 9 Hodgkin Disease 9 Glioblastoma 9 Lymphoma, B-Cell, Marginal Zone 8 Lung Neoplasms 8 Leukemia, Myeloid, Chronic-Phase 8 Gliosarcoma 7 Carcinoma, Non-Small-Cell Lung 7 Ovarian Neoplasms 6 Central Nervous System Neoplasms 6 Neoplasms 5

Interventions

sargramostim 1 Temozolomide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡